Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 19/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 13/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929163 | 1.00 | AKR1C3 (0.49) | AKR1C3AKR1C4AKR1C2AKR1C1 | |
| SCHEMBL17538032 | 0.80 | KDM4E (0.53) | AKR1C3AKR1C2 | |
| SCHEMBL4841031 | 0.80 | KDM4E (0.53) | AKR1C3 | |
| SCHEMBL4841041 | 0.80 | KDM4E (0.53) | AKR1C3 | |
| SCHEMBL3934286 | 0.80 | MMP13 (0.40) | — | |
| SCHEMBL8173545 | 0.77 | PKM (0.60) | — | |
| SCHEMBL8173551 | 0.77 | PKM (0.60) | — | |
| SCHEMBL15492141 | 0.76 | HDAC8 (0.52) | — | |
| SCHEMBL1003295 | 0.76 | TPMT (0.54) | — | |
| SCHEMBL6644786 | 0.76 | HDAC2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | AKR1C3 763/4885AKR1C4 1084/4885AKR1C2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.